Vident Advisory’s Bristol-Myers Squibb BMY Stock Holding History

Vident Advisory's BMY Position: Q2 2026 in Review

Vident Advisory reduced its Bristol-Myers Squibb (BMY) stake by 8.3% in Q2 2026, selling an estimated $1.27M and leaving 242,261 shares worth $14M. The position accounts for 0.1% of the portfolio, ranked #190.

Vident Advisory first reported a position in BMY in Q3 2023 and has held it in 12 quarters since. The position peaked at $42M in Q1 2024. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

• Vident Advisory held 242,261 shares of Bristol-Myers Squibb worth $14M as of Q2 2026.
• Vident Advisory sold 22,032 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.27M.
• Bristol-Myers Squibb made up 0.1% of Vident Advisory's portfolio in Q2 2026, its #190 holding.
• Vident Advisory first reported a position in Bristol-Myers Squibb in Q3 2023 and has held it in 12 quarters since.
• Vident Advisory's Bristol-Myers Squibb position peaked at $42M in Q1 2024.
• 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.